Immix Biopharma to Participate in Jefferies Global Healthcare Conference

The biotech company will host investor meetings at the upcoming industry event.

Apr. 10, 2026 at 3:42am

Got story updates? Submit your updates here. ›

A minimalist, glowing neon outline of a heart-shaped organ, pulsing with vibrant energy and highlighting the vital role of the heart in AL Amyloidosis, a rare and devastating disease.Immix Biopharma's innovative CAR-T therapy aims to restore the heart's function in AL Amyloidosis patients.Los Angeles Today

Immix Biopharma, Inc., the global leader in relapsed/refractory AL Amyloidosis, announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The company will be available for one-on-one meetings during the conference.

Why it matters

As a leading biotech company focused on a rare and devastating disease, Immix Biopharma's participation in major industry conferences like the Jefferies Global Healthcare Conference provides an opportunity to connect with investors, share updates on its pipeline, and raise awareness of its innovative therapies for AL Amyloidosis.

The details

Immix Biopharma is the global leader in relapsed/refractory AL Amyloidosis, a disease where the immune system produces toxic light chains that clog up vital organs. The company's lead candidate is NXC-201, a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy that is designed to teach the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is currently being evaluated in a U.S. multi-center study for relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy, and Orphan Drug Designation from the FDA and EMA.

  • The Jefferies Global Healthcare Conference will be held June 2-4, 2026 in New York, NY.

The players

Immix Biopharma, Inc.

A biotech company that is the global leader in relapsed/refractory AL Amyloidosis, a rare and devastating disease.

NXC-201

Immix Biopharma's lead candidate, a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy that is designed to teach the immune system to recognize and eliminate the source of the toxic light chains in AL Amyloidosis.

Got photos? Submit your photos here. ›

The takeaway

Immix Biopharma's participation in the Jefferies Global Healthcare Conference underscores its position as a leader in the fight against AL Amyloidosis, a rare and debilitating disease. The company's innovative CAR-T therapy, NXC-201, has received multiple designations from regulatory bodies, highlighting its potential to transform the treatment landscape for patients with this devastating condition.